Aethlon Medical Launches Hemopurifier® Cancer Trial at Royal Adelaide Hospital
Aethlon Medical Trial Activation
Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering therapeutic company dedicated to cancer treatment, has announced the activation of the Royal Adelaide Hospital for its Hemopurifier® Cancer Trial. This significant milestone allows the hospital to initiate patient screening and enrollment for the trial, which is expected to yield valuable data on innovative therapeutic approaches.
Overview of Hemopurifier® Technology
The Hemopurifier® is designed to remove circulating tumor cells and infectious pathogens from the blood, potentially enhancing the body’s ability to combat cancer. This trial represents a crucial step in validating the effectiveness of this technology in improving patient outcomes.
- Objective: Evaluate the efficacy of Hemopurifier® in patients with cancer.
- Participants: Eligible patients will undergo screening at Royal Adelaide Hospital.
- Significance: This trial could pave the way for novel cancer treatment modalities.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.